Innovative Product Focus Darmiyan has developed the FDA-approved BrainSee platform, emphasizing its commitment to cutting-edge brain health diagnostics that can significantly enhance clinical decision-making and personalized patient care, positioning it as a key provider in neurodegenerative disease management.

Recent Platform Launch The recent launch of the BrainSee Platform in September 2024 demonstrates Darmiyan's active expansion of scalable, FDA-approved solutions, presenting an opportunity to engage healthcare providers seeking advanced diagnostic tools for cognitive impairment.

Strategic Funding & Partnerships With recent funding totaling over $11 million including investments from notable entities like Eisai, Darmiyan has bolstered its financial foundation and validation, making it an attractive partner for collaborations and investment in brain health technologies.

Targeted Healthcare Market Darmiyan operates in a high-growth segment focused on brain health screening and monitoring, aligning with increasing demand from medical institutions for innovative, AI-driven diagnostic solutions for neurodegenerative conditions such as Alzheimer's disease.

Market Competitiveness Positioned alongside similar medtech firms with revenues up to 25 million dollars, Darmiyan has significant sales potential by expanding its user base among neurologists and geriatrics clinics seeking FDA-approved, scalable brain diagnostic tools.